Cellectar Shares Gain as Key Catalysts Approach

Cellectar Biosciences saw its shares advance significantly during Thursday’s trading session following the company’s announcement of its quarterly earnings date. The financial community is particularly focused on the upcoming November 13 presentation, where investors anticipate crucial updates regarding the new drug application for the cancer therapeutic iopofosine I 131.

Market analysts project a third-quarter loss of $1.91 per share for the biopharmaceutical company. However, historical performance provides a glimmer of optimism. During the preceding quarter, Cellectar surpassed expectations by reporting a loss of $3.39 per share, notably better than the forecasted $3.60 per share loss. This positive earnings surprise of 5.83% demonstrated the company’s potential to outperform projections.

The organization’s financial Read more...